<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253903</url>
  </required_header>
  <id_info>
    <org_study_id>LTE6262</org_study_id>
    <secondary_id>EucraCT: 2005-003082-16</secondary_id>
    <nct_id>NCT00253903</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year</brief_title>
  <acronym>EPLILONG</acronym>
  <official_title>Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: a 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study Followed by an Open Treatment Phase Extension With Eplivanserin for a 40-week Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess efficacy and safety of eplivanserin in the population
      of patients complaining of sleep maintenance insomnia. The patients suffering from that
      condition frequently wake up during the night, their sleep is nonrestorative and they suffer
      from a significant distress or impairment in their daily activities consecutive to insomnia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is being conducted worldwide.

      It consists of 4 segments:

        -  Segment A: 7-day run-in (screening)

        -  Segment B: 12-week double blind treatment

        -  Segment C: 40-week open treatment extension

        -  Segment D: 2-week run-out period
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of the mean pr-WASO (wake time after sleep onset using patient's sleep questionnaire)</measure>
    <time_frame>at week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of the mean of the FOSQ items 1 and 2 (concentration/memory)</measure>
    <time_frame>at week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of the mean of the FOSQ items 4 and 10 (hobby/work)</measure>
    <time_frame>at week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1155</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eplivanserin (SR46349)</intervention_name>
    <description>oral administration</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral administration</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Out patients

          -  Each patient must have primary insomnia in accordance with DSM-IV-TR-Axis I criteria

          -  Based on patient's information, the patient has spent at least 6.5 hours and not more
             than 9.0 hours, in bed, each night, over the preceding two weeks.

          -  Based on patient's information, the patient must complain of at least one hour of
             wakefulness after sleep onset for at least 3 nights per week over the preceding month

          -  Patient must report impact daytime functioning associated with sleep maintenance
             insomnia as measured by question 3 of Insomnia Severity Index at screening visit and
             randomization visit.

        Exclusion Criteria:

          -  Females who are lactating or pregnant

          -  Woman of childbearing potential with a positive serum beta human chorionic
             gonadotropin pregnancy test at screening and not using an acceptable form of
             contraception

          -  Patients presenting with acute or chronic pain resulting in insomnia

          -  Patients with history of epilepsy or seizures

          -  Consumption of xanthine containing beverage (i.e. tea, coffee, or cola) comprising
             more than 5 glasses/day

          -  Evidence of any clinically significant, severe, or unstable acute or chronically
             progressive medical or surgical disorder which may affect patient safety

          -  BMI &gt;32

          -  Acute or chronic pain resulting in insomnia

          -  Patients with current psychiatric disorders according to DSM-IV-TR criteria, mental
             retardation, or dementia

          -  Clinically significant and abnormal EKG (QTc interval &gt;500 msec)

          -  Positive for hepatitis B or C

          -  Serious head injury or stroke within 1 year

          -  Use of OTC medications such as valerian root, kava, melatonin, St. John's Wort, or
             alluna; prescription sleep medications or anxiolytics within 1 week or 5 half-lives

          -  Participation in another trial within two month before the screening visit

          -  Use of any substance with psychotropic effects or properties known to affect
             sleep/wake

          -  Unable to complete the study questionnaires

          -  Night shift workers, and individuals who nap 3 or more times per week over the
             preceding month

          -  History of:

               -  Primary hypersomnia

               -  Narcolepsy

               -  Breathing-related sleep disorder (such as sleep apnea)

               -  Circadian rhythm sleep disorder

               -  Parasomnia (somnambulism)

               -  Dyssomnia (such as periodic leg movements)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2005</study_first_submitted>
  <study_first_submitted_qc>November 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>November 29, 2010</last_update_submitted>
  <last_update_submitted_qc>November 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Primary Insomnia</keyword>
  <keyword>Sleeplessness</keyword>
  <keyword>Early Awakening</keyword>
  <keyword>Chronic Insomnia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>SR 46349B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

